TrialJournal of diabetes investigation2021

Dipeptidyl peptidase-4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes.

Takahiro Abe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.